Expanding HER2 horizons: Implications for NSCLC and beyond
touchPANEL DISCUSSION for touchONCOLOGY
Listen to three experts as they explore tissue-agnostic HER2 targeting in solid tumours, the latest clinical trial data for approved and emerging HER2-targeted therapies in NSCLC, and best practices for testing for HER2 alterations in NSCLC.
The experts
Dr Razelle Kurzrock - Medical Oncologist, Medical College of Wisconsin, Milwaukee, WI, USA
Dr Lyudmila Bazhenova - Medical Oncologist, UC San Diego Moores Cancer Center, San Diego, CA, USA
Dr Ignacio Wistuba - Pathologist, MD Anderson Cancer Center, Houston, TX, USA
This touchPODCAST is for HCPs outside…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.